CD274 and neoplasm: In the randomized population and tumor-cell PD-L1 expression of ≥1% subgroup, the nivolumab + chemotherapy group maintained higher complete response (CR) rates and longer-lasting responses at the 13-month follow-up than the other treatment groups.